InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Strategic Appointment of Quan A. Vu
November 3, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced it has named Quan A. Vu to the role of chief operating officer/chief business officer. Vu is a highly versatile and accomplished strategy, corporate/business development, finance and […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Preclinical Report on the CBG Impact on Pain, Inflammation, Obesity
October 26, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has published a preclinical study report on the effects of cannabigerol (“CBG”) derivatives on pain, inflammation and obesity. The report was published in the “Molecules” journal. ATNF has worked closely with […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Continues to Expand Portfolio, Pipeline and Patient Access to Innovative Therapies
September 30, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced its receipt of a Notice of Allowance from the United States Patent and Trade Office for application 16/661,769 “Method for Reducing Post-Operative Cognitive Dysfunction (‘POCD’).” According to […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF), Celltrion Healthcare Enter MOU for Strategic Supply Agreement
September 20, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced its entry into a memorandum of understanding (“MOU”) with Celltrion Healthcare, a leading biopharmaceutical company. The MOU is for the supply of an anti-TNF biosimilar drug used […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) CEO Releases Letter to Stockholders
August 30, 2021
180 Life Sciences (NASDAQ: ATNF) CEO Dr. James Woody issued a letter to stockholders of the clinical-stage biotechnology company that has its lead indication in phase 2b clinical trial and is focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain. The letter noted that the company has […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Closes $15M Private Placement
August 24, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has closed its previously announced private placement of 2,500,000 shares of its common stock and accompanying warrants to purchase an aggregate of up to 2,500,000 shares of common stock […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces $15M Private Placement
August 19, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has entered into securities purchase agreements with certain institutional investors. The intent is to raise approximately $15.0 million through the private placement of 2,500,000 shares […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Chair to Present Keynote at Autumn Scientific Meeting of BSSH
August 2, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced that board chairman Jagdeep Nanchahal will be presenting the keynote address at the upcoming British Society for Surgery of the Hand (“BSSH”) meeting. The meeting will be held […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Participate at BTIG Virtual Biotechnology Conference
July 29, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced its plans to participate at the BTIG Virtual Biotechnology Conference being held from Aug. 9-10, 2021. ATNF’s CEO Dr. James Woody and Professor Jagdeep Nanchahal, chairman of […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Selects Lead Synthetic CBD Analogue
July 28, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has selected a lead synthetic CBD analogue that is expected to move forward in clinical development for both inflammation and pain. According to the update, […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Regains Compliance with Nasdaq Listing Rule 5250(c)(1)
July 20, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has regained Nasdaq compliance under listing rule 5250(c)(1). As previously disclosed in the current report on Form 8-K, filed by 180 Life Sciences with the […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Regains Compliance with Nasdaq Listing Rules
July 12, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has regained Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2). As previously disclosed on the January 2021 report on Form 8-K, the Listing Qualifications Department […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Expansion of Scientific Fibrosis Platform
July 7, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that “Collagen VI as a driver and disease biomarker in human fibrosis” was published in the FEBS Journal as part of its State-of-the-Art Review series. The piece […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Joins Russell MicroCap Index, Files Quarterly Report Plan
June 28, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has been granted until July 31, 2021, to regain compliance with Nasdaq’s listing rule relating to untimely filings of its annual report for the year ended Dec. 31, 2020. The […]
DGE’s 2nd Medical Writing Innovation Strategies Conference for Life Sciences
June 14, 2021
Date: June 29-30, 2021Online Livestream Event Biopharma medical writing and communications professionals are invited are invited to attend DGE’s 2nd Medical Writing Innovation Strategies Conference for Life Sciences live streaming on June 29-30, 2021. The event will offer useful tips and guide medical professionals to learn innovative skills for filtering technical information that is effectively […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Names Two New Board Members with Vast Leadership Experience
June 10, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced two new appointments to its board of directors: Pamela Marrone, PhD, and Frank Knuettel II, MBA. Marrone has garnered vast experience over her 30-year career as a […]
InvestorNewsBreaks – Pressure BioSciences Inc. (PBIO) to Present at LD Micro Virtual Invitational Conference XI
June 8, 2021
Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of innovative, broadly enabling, pressure-based instruments, consumables and specialty testing services for the worldwide life sciences and other industries, today announced its participation in the upcoming LD Micro Virtual Invitational Conference XI. The three-day, virtual investor conference will feature approximately 180 companies, presenting […]
180 Life Sciences Corp. (NASDAQ: ATNF) Featured in Virtual Coverage of LD Micro’s Invitational XI
June 7, 2021
180 Life Sciences Corp. (NASDAQ: ATNF) is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Participation in LD Micro Invitational XI
June 1, 2021
180 Life Sciences (NASDAQ: ATNF) CEO will be presenting at the upcoming 2021 LD Micro Invitational XI. Dr. James Woody, head of 180 Life Sciences, a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, is slated to host a virtual presentation for investors […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Strategic Board Appointments
May 28, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has appointed Russell T. Ray, MBA and Teresa DeLuca MD, MBA to its board of directors, effective June 15, 2021. Ray formerly served as a […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Receipt of NASDAQ Letter, Will Submit Plan to Regain Compliance
May 24, 2021
180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (NASDAQ). The letter informed 180 Life Sciences that because it has not filed […]
InvestorNewsBreaks – Noble Capital Markets Inc. to Serve as Platinum-Level Sponsor of 16th Annual World Stem Cell Summit
May 17, 2021
Noble Capital Markets, a research-driven investment bank, on Friday announced its platinum-level sponsorship of the 16th World Stem Cell Summit, to be held virtually June 14-18, 2021. In addition, as part of its collaboration for the event, Noble will provide significant content through its small and microcap investor portal, Channelchek.com. Produced by the nonprofit Regenerative […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Collects 2b Disease Trial Data; Receives NASDAQ Notice Regarding Annual Report
April 20, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced collection of all patient data for its phase 2b Dupuytren’s disease trial, which was sponsored by the University of Oxford. The double-blind placebo-controlled trial involved 181 patients […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Colleague Receives 2021 International Dupuytren Award
April 14, 2021
180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced that Dr. Lynn Williams, PhD, has received the International Dupuytren Award 2021 for Basic Research. Williams’s research is sponsored by 180 Life Sciences. The award was […]
180 Life Sciences Corp. (NASDAQ: ATNF) Recognized R&D Pioneers in Anti-Inflammatory Therapeutics
March 26, 2021
NEW YORK, March 26, 2021 (GLOBE NEWSWIRE) — NetworkNewsAudio – 180 Life Sciences Corp. (NASDAQ: ATNF) announces the availability of a broadcast titled, “Controlling Inflammation to Stop Disease.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/VFpw9 Ongoing research and clinical trials for anti-tumor necrosis factor (anti-TNF) antibodies in autoimmune inflammatory […]
180 Life Sciences Corp. (NASDAQ: ATNF) in Hot Pursuit of New Anti-Inflammatory Blockbusters
March 25, 2021
NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) — via InvestorWire — 180 Life Sciences Corp. (NASDAQ: ATNF) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Controlling Inflammation to Stop Disease,” please visit: https://nnw.fm/VFpw9 Inflammation has […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) CEO Releases Stockholder Letter
March 24, 2021
180 Life Sciences Corp. (NASDAQ: ATNF) CEO James Woody, MD, PhD, has issued a letter to ATNF stockholders. In the letter he provides an overview of the company’s activities and accomplishments since his last stockholder letter, which was released in November 2020. The letter noted the company’s achievement in both legacy-related issues and strengthening its […]
InvestorNewsBreaks – MRVL Pet Pharmaceuticals(TM) Corp. to Collaborate with Altran for FDA Clinical Trials on Canine and Feline Cancer and Arthritis Treatment Products
March 17, 2021
MRVL Pet Pharmaceuticals(TM), a life sciences and technology company focused on the animal health sector, today announced its entry into an agreement with the Life Sciences division of Altran, a Capgemini company, to provide advisory services on their U.S. FDA clinical trial process for canine and feline cancer and arthritis products. According to the update, […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at Inaugural Emerging Growth Virtual Conference
March 8, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it will present at the Inaugural Emerging Growth Virtual Conference, hosted by M Vest LLC and Maxim Group LLC. The conference is slated to take place […]
InvestorNewsBreaks – Willow Biosciences Inc. (TSX: WLLW) (OTCQX: CANSF) Updates Status Regarding Acceleration of Expiry Date of Outstanding Warrants
March 3, 2021
Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, has released an update on the acceleration of common share warrants that was previously announced. Willow completed the acceleration, which was comprised of 9,320,478 common share purchase warrants issued on Oct. 29, 2020. The […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Closes on Private Placement with Gross Proceeds of $11.7M
February 25, 2021
180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced the closing of its previously announced private placement. The private placement included 2,564,000 shares of common stock and accompanying warrants, each share sold for a combined […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces $11.7M Private Placement
February 19, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced its entry into securities purchase agreements with certain institutional investors to raise approximately $11.7 million through the private placement of 2,564,000 shares of its common stock and […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at the Biotech Showcase(TM) Digital 2021 Conference
January 11, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it will present at the Biotech Showcase(TM) Digital 2021 Conference. According to the update, the conference is taking place […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at Upcoming H.C. Wainwright Bioconnect Conference
January 6, 2021
180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, on Tuesday announced that it will present at the H.C. Wainwright Bioconnect 2021 Conference. According to the update, the presentation will be […]
InvestorNewsBreaks – Pressure BioSciences Inc.’s (PBIO) PCT Platform Selected as ‘Method of Choice’ for Many Global Research Teams
December 17, 2020
Pressure BioSciences (OTCQB: PBIO) (“PBI”), a leader in the development and sale of pressure-based instruments, consumables and platform solutions to the worldwide biotechnology and other industries, today announced a remarkable convergence of global research teams declaring pivotal new insights into COVID-19 biology and disease processes. According to the update, all teams selected PBI’s Pressure Cycling […]
InvestorNewsBreaks – M Vest Unveils List of ‘Latest Companies in the Spotlight’
December 8, 2020
Various businesses were recently featured in M Vest LLC’s “Latest Companies in the Spotlight.” Featured companies in the latest list published by M Vest, a New York-based registered broker-dealer with the U.S. Securities and Exchange Commission (“SEC”) and member of FINRA and SIPC, include SELLAS Life Sciences Group Inc. (NASDAQ: SLS), Heritage Global Inc. (NASDAQ: […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at LD Micro Main Event
December 3, 2020
180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it will participate in the LD Micro Virtual Main Event 2020 Conference. According to the update, 180 Life […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Ring Nasdaq Opening Bell
November 24, 2020
180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that, in celebration of its recently completed initial public offering, it will ring the Nasdaq Stock Exchange opening bell […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Secures Additional Patents, Significantly Strengthening IP Portfolio
November 23, 2020
180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the continued expansion of its IP portfolio. According to the update, the company, on Nov. 20, 2020, received notice […]
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Issues Letter to Stockholders
November 17, 2020
180 Life Sciences (NASDAQ: ATNF, ATNFW), a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, on Monday released a letter to stockholders from its CEO Dr. James Woody. The letter addresses the closing of the merger […]